Clinical Trial Update: Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study of a sustained-release formulation of ruxolitinib in myelofibrosis, with results posted in Septe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2013-09-25